Metabolic syndrome

Signs and symptoms

The key sign of metabolic syndrome is central obesity, also known as visceral, male-pattern or apple-shaped adiposity. It is characterized by adipose tissue accumulation predominantly around the waist and trunk. Other signs of metabolic syndrome include high blood pressure, decreased fasting serum HDL cholesterol, elevated fasting serum triglyceride level, impaired fasting glucose, insulin resistance, or prediabetes. Associated conditions include hyperuricemia; fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease; polycystic ovarian syndrome in women and erectile dysfunction in men; and acanthosis nigricans.

Neck circumference

Neck circumference has been used as a simple surrogate index of upper-body subcutaneous fat. Values 40.25 cm (men) and 35.75 cm (women) are considered high risk for metabolic syndrome, and large neck circumference more than doubles risk. In adults with overweight/obesity, clinically significant weight loss may protect against COVID-19, and neck circumference has been associated with increased risk of mechanical ventilation and mortality in hospitalized COVID-19 patients.

Complications

Metabolic syndrome can lead to type 2 diabetes, cardiovascular diseases, stroke, kidney disease and nonalcoholic fatty liver disease. It is also associated with a significantly increased risk of surgical complications across most types of surgery in a 2023 systematic review and meta-analysis of 13 million individuals.

Causes

The mechanisms underlying metabolic syndrome are under investigation and only partially elucidated. Most affected people are older, obese, sedentary, and have some degree of insulin resistance. Stress can also contribute. Important risk factors include diet (particularly sugar-sweetened beverages), genetics, aging, sedentary behaviour or low physical activity, disrupted chronobiology/sleep, mood disorders and some medications, and excessive alcohol use. The pathogenic role of excessive adipose expansion under sustained overeating and resulting lipotoxicity has also been proposed.

Markers of systemic inflammation including C-reactive protein, fibrinogen, interleukin 6, and tumor necrosis factor-alpha (TNF-α) are often increased. Some research has focused on increased uric acid levels from dietary fructose.

Modern "Western diet" patterns with high intake of energy-dense processed foods are a factor in the development of metabolic syndrome. Rather than total adiposity, the core clinical component is visceral/ectopic fat, and the principal metabolic abnormality is insulin resistance. A chronic energy surplus unmatched by activity may lead to mitochondrial dysfunction and insulin resistance.

Stress

Prolonged chronic stress may contribute to metabolic syndrome via dysregulation of the hypothalamic–pituitary–adrenal axis. Elevated cortisol can raise glucose and insulin levels, promoting visceral adiposity, insulin resistance, dyslipidaemia, and hypertension, and has effects on bone turnover.

Pathophysiology

It is common for there to be a development of visceral fat, after which adipocytes increase plasma levels of TNF-α and alter levels of other adipokines (e.g., adiponectin, resistin, PAI-1). TNF-α can induce inflammatory cytokines and may trigger insulin resistance. Rat models with high-sucrose diets have shown progression from hypertriglyceridaemia to visceral fat accumulation and insulin resistance. Increased adipose tissue elevates immune cells and chronic inflammation, contributing to hypertension, atherosclerosis and diabetes.

The endocannabinoid system may contribute to metabolic dysregulation. Overproduction can alter reward circuitry and executive function, perpetuating unhealthy behaviours. The brain modulates peripheral carbohydrate and lipid metabolism. Overfeeding with sucrose/fructose, particularly with high-fat intake, can induce features of metabolic syndrome in animals. Arachidonic acid–derived mediators (eicosanoids; 2-arachidonoylglycerol; anandamide) may link lipid oversupply and inflammation.

Diagnosis

NCEP

As of 2023, the U.S. National Cholesterol Education Program Adult Treatment Panel III (2001) remains widely used. It requires at least three of the following:

• Central obesity: waist circumference ≥102 cm (40 in) men; ≥88 cm (35 in) women
• Dyslipidaemia: TG ≥1.7 mmol/L (150 mg/dL)
• Dyslipidaemia: HDL-C
• Blood pressure ≥130/85 mmHg (or treated for hypertension)
• Fasting plasma glucose ≥6.1 mmol/L (110 mg/dL)

2009 Interim Joint Statement

The International Diabetes Federation Task Force and partner organisations harmonised criteria in 2009. Diagnosis is three or more of:

• Elevated waist circumference (population- and country-specific)
• Triglycerides ≥150 mg/dL (1.7 mmol/L)
• Reduced HDL-C (≤40 mg/dL (1.0 mmol/L) men; ≤50 mg/dL (1.3 mmol/L) women)
• Elevated blood pressure (systolic ≥130 and/or diastolic ≥85 mmHg)
• Fasting glucose ≥100 mg/dL (5.55 mmol/L)

This statement recognises population differences in waist risk thresholds and encourages common criteria with agreed cut points for international comparisons.

The prior IDF and revised NCEP definitions are similar, but differ on assumptions when body mass index ≥30 kg/m2 and on geography-specific waist cut points.

WHO

The World Health Organization (1999) requires one of diabetes mellitus, impaired glucose tolerance, impaired fasting glucose or insulin resistance and two of:

• Blood pressure ≥140/90 mmHg
• Dyslipidemia: TG ≥1.695 mmol/L and HDL-C ≤0.9 mmol/L (men), ≤1.0 mmol/L (women)
• Central obesity: waist:hip ratio 0.90 (men); 0.85 (women), or BMI 30 kg/m2
• Microalbuminuria: urinary albumin excretion ≥20 μg/min or albumin:creatinine ≥30 mg/g

EGIR

The European Group for the Study of Insulin Resistance (1999) requires insulin resistance (top 25% fasting insulin among nondiabetic individuals) and two or more of:

• Central obesity: waist ≥94 cm (37 in) men; ≥80 cm (31.5 in) women
• Dyslipidaemia: TG ≥2.0 mmol/L (177 mg/dL) and/or HDL-C
• Blood pressure ≥140/90 mmHg or antihypertensive medication
• Fasting plasma glucose ≥6.1 mmol/L (110 mg/dL)

Cardiometabolic index

The Cardiometabolic Index (CMI) estimates risk of type 2 diabetes, non-alcoholic fatty liver disease, and metabolic issues from waist-to-height ratio and triglycerides-to-HDL-C ratio. CMI has also been explored alongside cardiovascular disease and erectile dysfunction. Anti-inflammatory dietary patterns may improve related markers.

Other

High-sensitivity C-reactive protein is used to predict cardiovascular risk in metabolic syndrome and may predict nonalcoholic fatty liver disease. Reproductive disorders (such as polycystic ovary syndrome in women of reproductive age) and erectile dysfunction or decreased total testosterone in men have also been associated.

Prevention

Prevention of metabolic syndrome centres on improving modifiable lifestyle factors that contribute to excess visceral fat, insulin resistance, and cardiometabolic risk. Even modest, sustained changes in activity and diet have been shown to improve multiple components of the syndrome.

Regular physical activity is strongly supported by clinical and public-health organizations. Guidelines from the American Heart Association recommend at least 150 minutes per week of moderate-intensity aerobic activity, or 75 minutes of vigorous activity, with additional muscle-strengthening exercises on two or more days per week. Walking—even in shorter bouts that accumulate to 30 minutes per day—is associated with measurable improvements in blood pressure, insulin sensitivity, and waist circumference.

Dietary patterns emphasizing whole foods appear beneficial. Evidence from observational studies and randomized trials supports Mediterranean-style eating, which is associated with reduced central adiposity and improved lipid and glycaemic measures. Calorie reduction, improved diet quality, and lowering intake of refined carbohydrates also contribute to improved metabolic parameters. Time-restricted eating (a form of intermittent fasting) has shown preliminary benefits in reducing waist circumference and fasting glucose in adults with metabolic syndrome, though long-term effects remain under investigation.

Other behavioural factors influence prevention outcomes. Adequate sleep duration and quality have been linked to lower cardiometabolic risk, with insufficient sleep associated with higher rates of hypertension, obesity, and dysregulated glucose metabolism. Reducing alcohol intake may also be protective, as heavy use can worsen hepatic and metabolic outcomes in people with underlying metabolic risk.

Although individual-level changes are effective for many people, adherence varies widely in real-world settings. Public-health bodies—including the International Obesity Taskforce—argue that sustained prevention requires population-level interventions, such as improved access to healthy foods, urban design that supports physical activity, and policies addressing socioeconomic drivers of obesity.

Management

Management focuses on reducing cardiovascular and metabolic risk through lifestyle modification, pharmacologic therapy, and, in selected cases, surgery. Because metabolic syndrome represents a cluster of interrelated conditions, treatment typically targets each component individually rather than the syndrome as a single entity.

Diet and meal timing

A Mediterranean-style eating pattern—emphasising vegetables, fruits, whole grains, legumes, nuts, and unsaturated fats—is associated with improvements in blood pressure, lipids, insulin sensitivity, and cardiovascular risk. Reduced-carbohydrate approaches may lower glucose and promote weight loss in insulin-resistant individuals. Evidence on meal timing suggests time-restricted eating or avoidance of late-night meals can modestly improve glycaemic and lipid markers, though long-term data are limited. Guidance recommends tailoring dietary advice to personal preference, culture, and access to improve adherence.

Follow-up and equity considerations

Ongoing follow-up includes monitoring waist circumference, body weight, blood pressure, lipids, and fasting glucose or HbA1c. Recent guidance emphasises equitable care through culturally appropriate counselling, affordable medication access, and community-based support.

Medications and therapies

Treatment of individual risk factors follows established cardiovascular and diabetes guidelines.

• Blood pressure: First-line agents include thiazide-type diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and calcium channel blockers. Selection depends on comorbid conditions and tolerance.
• Dyslipidaemia: Statins remain first-line therapy for lowering low-density lipoprotein cholesterol (LDL-C). Fibrates or omega-3 fatty acids may be added for persistent severe hypertriglyceridaemia.
• Glucose control: Lifestyle intervention is the foundation of therapy. When medications are required, glucose-lowering agents with demonstrated cardiovascular and renal benefits—such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors—are preferred for individuals with type 2 diabetes or elevated cardiovascular risk.
• Obesity management: Pharmacotherapies such as semaglutide and tirzepatide produce clinically significant weight loss and improvements in blood pressure, lipids, and glycaemic control. Randomized controlled trials have reported reduced major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease.

Physical activity and weight reduction

Weight loss of ~7–10% over 6–12 months improves BP, lipids, and insulin sensitivity.

Sleep, tobacco, and alcohol

Inadequate/irregular sleep and untreated obstructive sleep apnoea increase metabolic and CV risk. Smoking increases insulin resistance and CV risk; cessation reduces adverse outcomes. High alcohol intake raises BP, TGs, and hepatic steatosis; moderation is advised.

Surgery

Metabolic (bariatric) surgery is considered when lifestyle and pharmacotherapy are insufficient. Surgery is associated with durable weight loss and partial or complete remission of type 2 diabetes, hypertension, and dyslipidaemia. Guidelines endorse surgery for BMI ≥35 kg/m², or ≥30 kg/m² with metabolic complications.

Epidemiology

Main article: Epidemiology of metabolic syndrome

Approximately 20–25% of the world's adults have metabolic syndrome. In 2000, ~32% of U.S. adults met criteria; more recent estimates are ~34%.

In young children, there is no consensus on measurement; age-specific cut points are not well established. Continuous risk scores are often used instead. Microbiome composition and some conditions have been associated with metabolic syndrome, sometimes with gender-specific patterns.

History

In 1921, Joslin reported the association of diabetes with hypertension and hyperuricaemia. In 1923, Kylin expanded on this triad. In 1947, Vague observed that upper-body obesity predisposed to diabetes, atherosclerosis, gout and calculi. The term metabolic syndrome began appearing in the late 1950s. In 1967, Avogaro, Crepaldi and coworkers described moderately obese people with diabetes, hypercholesterolemia, and marked hypertriglyceridemia that improved on hypocaloric, low-carbohydrate diets. In 1977, Haller used the term for associations of obesity, diabetes mellitus, hyperlipoproteinemia, hyperuricemia, and hepatic steatosis. The same year, Singer used it for associations of obesity, gout, diabetes, and hypertension with hyperlipoproteinemia. In 1977–1978, Gerald B. Phillips proposed a "constellation of abnormalities" (glucose intolerance, hyperinsulinemia, hypercholesterolemia, hypertriglyceridemia, hypertension) and hypothesised sex hormones as a linking factor. In 1988, Gerald M. Reaven's Banting lecture proposed insulin resistance as the underlying factor and coined syndrome X.

References

References

1. "Metabolic syndrome". Mayo Clinic.
2. (July 2014). "Prevalence of metabolic syndrome and obesity-associated hypertension in the racial ethnic minorities of the United States". Current Hypertension Reports.
3. (August 2013). "Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999–2010". Journal of the American College of Cardiology.
4. Anagnostis, Panagiotis. (November 30, 2023). "Metabolic Syndrome". BMJ Best Practice.
5. (15 January 2019). "Metabolic Syndrome".
6. (March 2018). "Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic". Toxicological Sciences.
7. (2023-06-13). "Evaluating Neck Circumference as an Independent Predictor of Metabolic Syndrome and Its Components Among Adults: A Population-Based Study". Cureus.
8. (2023-10-13). "Association of adiposity and its changes over time with COVID-19 risk in older adults with overweight/obesity and metabolic syndrome: a longitudinal evaluation in the PREDIMED-Plus cohort". BMC Medicine.
9. (2021). "Neck circumference as reliable predictor of mechanical ventilation support in adult inpatients with COVID-19: A multicentric prospective evaluation". Diabetes/Metabolism Research and Reviews.
10. (2021-12-10). "Neck Circumference Predicts Mortality in Hospitalized COVID-19 Patients". Infectious Disease Reports.
11. "Metabolic syndrome – Symptoms and causes".
12. (2 November 2023). "Metabolic syndrome and surgical complications: A systematic review and meta-analysis of 13 million individuals". International Journal of Surgery.
13. (November 2010). "Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis". Diabetes Care.
14. (September 2006). "Genetic determinants of the metabolic syndrome". Nature Clinical Practice Cardiovascular Medicine.
15. (May 2001). "Genetic versus environmental aetiology of the metabolic syndrome among male and female twins". Diabetologia.
16. (March 2000). "Genetics of the metabolic syndrome". The British Journal of Nutrition.
17. (May 1995). "Genetics and the metabolic syndrome". International Journal of Obesity and Related Metabolic Disorders.
18. (2012). "Association of sedentary behaviour with metabolic syndrome: a meta-analysis". PLOS ONE.
19. (October 2003). "Targeting the metabolic syndrome with exercise: evidence from the HERITAGE Family Study". Medicine and Science in Sports and Exercise.
20. (June 2014). "Association between leisure time physical activity and metabolic syndrome: a meta-analysis of prospective cohort studies". Endocrine.
21. (August 2014). "Short sleep duration predicts risk of metabolic syndrome: a systematic review and meta-analysis". Sleep Medicine Reviews.
22. (July 2014). "Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables". Psychological Medicine.
23. (March 2013). "Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators". The American Journal of Psychiatry.
24. (August 2014). "Alcohol consumption and risk of metabolic syndrome: a meta-analysis of prospective studies". Clinical Nutrition.
25. (2013). "Adipose tissue expandability, lipotoxicity and the metabolic syndrome". Endocrinologia y Nutricion.
26. (March 2006). "A causal role for uric acid in fructose-induced metabolic syndrome". American Journal of Physiology. Renal Physiology.
27. (June 1990). "Metabolic effects of dietary fructose". FASEB Journal.
28. (May 1989). "Blood lipids, lipoproteins, apoproteins, and uric acid in men fed diets containing fructose or high-amylose cornstarch". The American Journal of Clinical Nutrition.
29. (March 2012). "Toward a unifying hypothesis of metabolic syndrome". Pediatrics.
30. (September 2016). "The glucagon-like peptide-1 analogue exendin-4 reverses impaired intracellular Ca(2+) signalling in steatotic hepatocytes". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.
31. (2012). "Toward a Unifying Hypothesis of Metabolic Syndrome". Pediatrics.
32. (July 2001). "Hypothalamic-pituitary-adrenal axis function and the metabolic syndrome X of obesity". CNS Spectrums.
33. (October 2002). "Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress". Journal of Psychosomatic Research.
34. (February 2000). "The hypothalamic-pituitary-adrenal axis activity as a predictor of cardiovascular disease, type 2 diabetes and stroke". Journal of Internal Medicine.
35. (November 2002). "Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study". Circulation.
36. (June 1999). "The role of TNFalpha and TNF receptors in obesity and insulin resistance". Journal of Internal Medicine.
37. Whitney, Ellie; Ralfes, R. Sharon. 2011. ''Understanding Nutrition''. [[Wadsworth Cengage Learning]]: Belmont, CA.
38. (2018). "Abdominal obesity and metabolic syndrome: exercise as medicine?". BMC Sports Sci Med Rehabil.
39. (2015). "Endocannabinoids".
40. (March 2008). "Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome". Physiology & Behavior.
41. (June 2004). "Role of fatty acid composition in the development of metabolic disorders in sucrose-induced obese rats". Experimental Biology and Medicine.
42. (Dec 1994). "Formation and inactivation of endogenous cannabinoid anandamide in central neurons". Nature.
43. (June 2015). "Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites". Journal of Leukocyte Biology.
44. Expert Panel On Detection, Evaluation. (May 2001). "Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults". JAMA.
45. (October 2009). "Harmonizing the metabolic syndrome: a joint interim statement...". Circulation.
46. (1999). "Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications". World Health Organization.
47. Balkau B, Charles MA. (May 1999). "Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR)". Diabet Med.
48. (2022-01-06). "Metabolic Obesity in People with Normal Body Weight (MONW) – Review of Diagnostic Criteria". MDPI AG.
49. (2019). "Male sexual dysfunction: A review of literature on its pathological mechanisms, potential risk factors, and herbal drug intervention". Elsevier BV.
50. (2022-09-26). "Beneficial Effects of Anti-Inflammatory Diet in Modulating Gut Microbiota and Controlling Obesity". MDPI AG.
51. (2009). "High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population". Journal of Gastroenterology.
52. (February 2011). "Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies". International Journal of Epidemiology.
53. Joseph, Jimmy. (July 3, 2025). "The Impact of Semaglutide on Metabolic Syndrome: A Case Report". Cureus.
54. (10 March 2024). "AHA recommendations for physical activity in adults".
55. (September 2010). "Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US". Journal of Diabetes.
56. (October 2004). "Increasing prevalence of the metabolic syndrome among U.S. Adults". Diabetes Care.
57. (January 2011). "Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999–2006". Diabetes Care.
58. (December 2018). "Continuous cardiometabolic risk score definitions in early childhood: a scoping review". Obesity Reviews.
59. (October 2017). "Early diagnosis of metabolic syndrome in children". The Lancet. Child & Adolescent Health.
60. (January 2021). "Gut microbiota in human metabolic health and disease". Nature Reviews Microbiology.
61. (2023-04-10). "Association between metabolic syndrome components and gingival bleeding is women-specific: a nested cross-sectional study". Journal of Translational Medicine.
62. (1921). "The Prevention of Diabetes Mellitus". JAMA.
63. (1923). "[Studies of the hypertension-hyperglycemia-hyperuricemia syndrome]". Zentralbl Inn Med.
64. (1947). "La différenciation sexuelle, facteur déterminant des formes de l'obésité.". Presse Med.
65. (1967). "Associazione di iperlipemia, diabete mellito e obesita' di medio grado". Acta Diabetologica Latina.
66. (April 1977). "[Epidermiology and associated risk factors of hyperlipoproteinemia]". Zeitschrift für Sie Gesamte Innere Medizin und Ihre Grenzgebiete.
67. (May 1977). "[Diagnosis of primary hyperlipoproteinemias]". Zeitschrift für die Gesamte Innere Medizin und Ihre Grenzgebiete.
68. (July 1978). "Sex hormones, risk factors and cardiovascular disease". The American Journal of Medicine.
69. (April 1977). "Relationship between serum sex hormones and glucose, insulin and lipid abnormalities in men with myocardial infarction". Proceedings of the National Academy of Sciences of the United States of America.
70. (December 1988). "Banting lecture 1989. Role of insulin resistance in human disease". Diabetes.
71. American Diabetes Association. (2024). "Standards of Care in Diabetes—2024". Diabetes Care.
72. Angrisani, L. (2023). "Bariatric surgery worldwide 2023 update". Obes Surg.
73. Dominguez, LJ. (2023). "Mediterranean diet in the management and prevention of metabolic syndrome". Nutrition Metab Cardiovasc Dis.
74. Eshera, YM. (2023). "Sleep is essential for cardiovascular health". Curr Probl Cardiol.
75. Feinman, RD. (2015). "Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base". Nutrition.
76. Frias, JP. (2022). "Tirzepatide once weekly for the treatment of obesity". N Engl J Med.
77. Giangregorio, F. (2024). "A systematic review of metabolic syndrome: key findings and practical insights". J Clin Med.
78. Grundy, SM. (2005). "Diagnosis and management of the metabolic syndrome". Circulation.
79. Hagström, H. (2024). "Interactions between metabolic syndrome and alcohol consumption increase liver disease risk". United European Gastroenterol J.
80. "Metabolic syndrome".
81. Manoogian, ENC. (2024). "Time-restricted eating in adults with metabolic syndrome". Ann Intern Med.
82. Mirghani, H. (2023). "Metabolic surgery versus usual care: effects on diabetes and metabolic risk". Diabetol Metab Syndr.
83. Peterseim, CM. (2024). "Metabolic syndrome: an updated review on diagnosis and treatment". J Prim Care Community Health.
84. Swarup, S. (2024). "Metabolic Syndrome". StatPearls Publishing.
85. Wilding, JPH. (2021). "Once-weekly semaglutide in adults with overweight or obesity". N Engl J Med.